Correlations between 25(OH)D and BMD change in postmenopausal osteoporotic women : secondary analyses of a 1-year trial of weekly alendronate (ALN) plus vitamin D3 5600 IU vs. standard care

in Osteoporosis International (2012, March), 23(S2), 238-239

Strontium ranelate uncouples bone formation from bone resorption in male osteoporotic patients

in Osteoporosis International (2012, March), 23(S2), 365-366

Perception, knowledge and use by general practitioners of Belgium of the FRAX tool

in Osteoporosis International (2012, March), 23(Suppl. 2), 363-364

Prediction of future knee surgery in patient with osteoarhtritis by the use of a new definition of x-ray progression

in Osteoporosis International (2012, March), 23(Suppl. 2), 363

Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study

in Osteoporosis International (2012, March), 23(Suppl. 2), 361-362

Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement

in Osteoporosis International (2012, March), 23(Suppl. 2), 129-130

An economic evaluation of strontium ranelate for the treatment of male osteoporosis

in Osteoporosis International (2012, March), 23(Suppl. 2), 305-306

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension.

in Journal of Bone and Mineral Research (2012), 27(3), 694-701

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment of postmenopausal women with osteoporosis. Participants who completed FREEDOM were eligible to ... [more ▼]

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment of postmenopausal women with osteoporosis. Participants who completed FREEDOM were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up to 10 years. For the extension results presented here, women from the FREEDOM denosumab group had 2 more years of denosumab treatment (long-term group) and those from the FREEDOM placebo group had 2 years of denosumab exposure (cross-over group). We report results for bone turnover markers (BTMs), bone mineral density (BMD), fractures rates, and safety. A total of 4550 women enrolled in the extension (2343 long-term; 2207 cross-over). Reductions in BTMs were maintained (long-term group) or occurred rapidly (cross-over group) following denosumab administration. In the long-term group, lumbar spine and total hip BMD increased further, resulting in 5-year gains of 13.7% and 7.0%, respectively. In the cross-over group, BMD increased at the lumbar spine (7.7%) and total hip (4.0%) during the 2-year denosumab treatment. Yearly fracture incidences for both groups were below rates observed in the FREEDOM placebo group and below rates projected for a "virtual untreated twin" cohort. Adverse events did not increase with long-term denosumab administration. Two adverse events in the cross-over group were adjudicated as consistent with osteonecrosis of the jaw (ONJ). Five-year denosumab treatment of women with postmenopausal osteoporosis maintained BTM reduction and increased BMD, and was associated with low fracture rates and a favorable risk/benefit profile. (c) 2011 American Society for Bone and Mineral Research. [less ▲]

A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.

in Statistical Methods in Medical Research (2012)

Relationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment

in Arthritis and Rheumatism (2012), 64(S10), 847